Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""van Oort, I. M."" wg kryterium: Autor


Tytuł :
De dilemma’s van de nieuwe behandelmogelijkheden voor castratieresistent prostaatcarcinoom (CRPC); een filosofische kijk op de toekomst
Autorzy :
van Oort, I. M.
Pokaż więcej
Źródło :
Tijdschrift voor Urologie. April 2012 2(2):50-52
Czasopismo naukowe
Tytuł :
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Autorzy :
Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands. .; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands. .
Kuppen MCP; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.
van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
de Wit R; Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
Bergman AM; Division of Internal Medicine (MOD) and Oncogenomics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
van Moorselaar RJA; Department of Urology, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
Coenen JLLM; Department of Internal Medicine, Isala Klinieken, Zwolle, the Netherlands.
van den Bergh ACM; Department of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands.
Somford DM; Department of Urology, Canisius Wilhemina Hospital, Nijmegen, the Netherlands.
Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.
Aben KKH; Department for Health Evidence, Radboud University Medical Center, The Netherlands and Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Uyl-de Groot CA; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.
Pokaż więcej
Źródło :
Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2021 Mar 21. Date of Electronic Publication: 2021 Mar 21.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
Autorzy :
Boerrigter E; Department of Pharmacy, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Benoist GE; Department of Pharmacy, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
van Oort IM; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Verhaegh GW; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
van Hooij O; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Groen L; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Smit F; MDxHealth, Nijmegen, The Netherlands.
Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, The Netherlands.
de Mol P; Department of Medical Oncology, Gelderse Vallei Hospital, Ede, The Netherlands.
Smilde TJ; Department of Medical Oncology, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands.
Somford DM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Mehra N; Deparment of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands.
Schalken JA; Department of Urology, Radboud university medical center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
van Erp NP; Department of Pharmacy, Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2021 Mar 02. Date of Electronic Publication: 2021 Mar 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients.
Autorzy :
van Steenbergen TRF; Department of Radiology and Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. .
Smits M; Department of Medical Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Scheenen TWJ; Department of Radiology and Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
van Oort IM; Department of Urology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Nagarajah J; Department of Radiology and Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Rovers MM; Department of Operating Rooms, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Mehra N; Department of Medical Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Fütterer JJ; Department of Radiology and Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2020 Jan; Vol. 43 (1), pp. 147-154. Date of Electronic Publication: 2019 Aug 23.
Typ publikacji :
Journal Article
MeSH Terms :
Oligopeptides*
Bone Neoplasms/*pathology
Cone-Beam Computed Tomography/*methods
Diffusion Magnetic Resonance Imaging/*methods
Edetic Acid/*analogs & derivatives
Positron Emission Tomography Computed Tomography/*methods
Prostatic Neoplasms, Castration-Resistant/*pathology
Aged ; Bone Neoplasms/diagnostic imaging ; Bone Neoplasms/secondary ; Bone and Bones/diagnostic imaging ; Bone and Bones/pathology ; Humans ; Image-Guided Biopsy ; Male ; Middle Aged ; Pilot Projects ; Prospective Studies ; Radiography, Interventional/methods ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
Autorzy :
van Oort IM; Department of Urology, Radboud University Nijmegen Medical Centre, PO BOX 9101, 6500 HB Nijmegen, the Netherlands.
Schout BM
Kiemeney LA
Hulsbergen CA
Witjes JA
Pokaż więcej
Źródło :
European urology [Eur Urol] 2005 Oct; Vol. 48 (4), pp. 572-6.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Prostatectomy*
Biomarkers, Tumor/*blood
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*pathology
Prostatic Neoplasms/*surgery
Disease Progression ; Disease-Free Survival ; Follow-Up Studies ; Humans ; Male ; Neoplasm Invasiveness ; Neoplasm Staging ; Predictive Value of Tests ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms/immunology ; Retrospective Studies ; Risk Factors ; Seminal Vesicles/pathology ; Treatment Outcome ; Tumor Burden
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies